mRNA technology is crucial for its rapid development capabilities, adaptability and potential in responding to infectious diseases.
Quantoom’s Ntensify midi system is designed to enable the production of high-yield, low-contaminant mRNA with unparalleled quality.
The system provides a GMP-grade, scalable and automated solution from Phase I to commercial, making it ideal for vaccine developers like Inventprise.
Integrating Quantoom’s technology with Inventprise’s vaccine development expertise enhances the potential to deliveriaffordable mRNA vaccines to underserved populations.
As a proof of concept, Inventprise is developing an RSV vaccine using Quantoom’s Ntensify solution to optimise the end-to-end process.
The project is supported with funding from the Gates Foundation.
The company also plans to apply the technology beyond RSV, ensuring rapid, scalable vaccine production in response to emerging infectious diseases. This strengthens Inventprise’s role in pandemic preparedness.
Leadership perspectives
“The Quantoom midi system allows us to produce high-quality GMP mRNA vaccines quickly, addressing infectious disease challenges in our pursuit of improving global health,” said Yves Leurquin, President and CEO of Inventprise.
“We are honoured that Inventprise has chosen our Ntensify technology to advance their RSV mRNA vaccine programme,” said José Castillo, CEO of Quantoom Biosciences.
“This milestone represents a major step in evolving mRNA vaccines beyond COVID-19 to protect vulnerable populations."
"Our collaboration reinforces our commitment to making high-quality, scalable mRNA production accessible to vaccine developers worldwide.”